Additionally, CTC phenotypic changes have been investigated in breast cancer irrespective of HER2-positive or -negative status; it was found that CTCs are heterogenous compared to primary tumors and phenotyping CTCs are critical in stratifying patients for HER2-targeted therapy [168]. This evidence concerns the gene ERBB2 and breast carcinoma.